Abstract:
This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramide derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer such as NUC-3373 (5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3'-deoxyadenosine-5'-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations which comprise a polar aprotic solvent, for example dimethyl acetamide (DMA).
Formulations of phosphoramidate derivatives of nucleoside drugs

[0001] This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer such as NUC-3373 (5-fluoro-2'-deoxyuridine-5'-0-[1-naphthyl (benzoxyl-L-alaninyl)] phosphate), NUC-7738 (3'-deoxyadenosine-5'-0-[phenyl(benzyloxy-L-alaninyl)] phosphate) and CPF-448 (2-chloro-2'-beta-fluoro-2'-deoxyadenosine-5'- [phenyl-(benzoxyl-L-(alaninyl)]-phosphate). In particular, the invention relates to formulations which comprise a polar aprotic solvent, for example dimethyl acetamide (DMA).

BACKGROUND

[0002] Protides are masked phosphate derivatives of nucleosides. They have been shown to be particularly potent therapeutic agents in the fields of both antivirals and oncology. Protides, more specifically, are prodrugs of monophosphorylated nucleosides. These compounds appear to avoid many of the inherent and acquired resistance mechanisms which limit the utility of the parent nucleosides (see, for example, 'Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development'; Slusarczyk et al; J. Med. Chem.; 2014, 57, 1531-1542).

[0003] NUC-3373 (5-fluoro-2'-deoxyuridine-5'-0-[1-naphthyl (benzoxyl-L-alaninyl)] phosphate) is a protide adaptation of 5FU/FUDR, the current foundation treatment against colorectal cancer. NUC-3373 and a range of related compounds have shown activity in vitro against a range of cancer models, in many cases and in particular for NUC-3373 that activity was outstanding and far superior to the results obtained with 5-fluorouracil. The addition of the protide phosphoramidate moiety to the 5-fluorouracil/FUDR molecule confers the specific advantages of delivering the key activated form of the agent (FdUMP) into the tumour cells. Non clinical studies have demonstrated that NUC-3373 overcomes the key cancer cell resistance mechanisms associated with 5-FU and its oral pro-drug capecitabine, generating high intracellular levels of the active FdUMP metabolite, resulting in a much greater inhibition of tumour cell growth. Furthermore, in formal dog toxicology studies, NUC-3373 is significantly better tolerated than 5-FU (see WO2012/1 17246; McGuigan et al.; Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside; J. Med. Chem.; 2011, 54, 7247-7258; and Vande Voorde et al.; The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is
independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes; Biochem. Pharmacol.; 2011, 82, 441-452).

[0004] Protide derivatives of purine nucleosides such as clofarabine and deoxyadenosine and related compounds have also shown excellent activity in vitro against a range of solid tumors, leukaemias and lymphomas (see WO2006/100439 and WO2016/083830 (PCT/GB2015/053628)). Deoxyadenosine itself is not a particularly potent anticancer agent.

[0005] Unfortunately, protides are often extremely lipophilic and thus poorly water soluble, and the ionisable moieties, tend to have calculated pKa values which lie outside the pH range suitable for parenteral administration. Many are essentially insoluble in water, regardless of salt content or pH within physiological ranges, and this puts limitations on the development of clinically acceptable methods for delivering the compounds at sufficiently high dosages for effective treatment.

[0006] It is an aim of certain embodiments of this invention to provide a pharmaceutical formulation of protides that delivers an effective dose.

[0007] It is an aim of certain embodiments of this invention to provide a stable pharmaceutical formulation of protides. For intravenous administration, suitable infusion formulations typically should be stable for greater than 30 minutes and up to 48 hours. Typically, for intravenous administration the formulation should be stable both to precipitation of the protide and to degradation of the protide.

[0008] It is an aim of certain embodiments of this invention to provide a pharmaceutical formulation of the protide which delivers an effective dose intravenously.

[0009] It is an aim of certain embodiments of this invention to provide a parenteral formulation of the protide which can be administered in either a peripheral vein or via a Central Venous Access Device (CVAD). Thus, it is an aim of certain embodiments of this invention to provide a formulation which has an osmolarity and pH that are acceptable for administration via a peripheral vein. It may be that the osmolarity and pH are such that the level of pain experienced by the patient is acceptable.

[0010] Certain embodiments of this invention satisfy some or all of the above aims.

**BRIEF SUMMARY OF THE DISCLOSURE**

[0011] In accordance with a first aspect of the present invention there is provided a pharmaceutical formulation comprising:

- a protide;
- a polar aprotic solvent; and
optionally one or more pharmaceutically acceptable excipients;
wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate (NUC-1031).

[0012] The polar aprotic solvent may be selected from dimethylacetamide (DMA) dimethylsulfoxide (DMSO) and N-methyprrolidone (NMP). Preferably, the polar aprotic solvent is DMA. In an alternative preferred embodiment, the polar aprotic solvent is NMP. For certain protides, DMA offers the best solubility profile of those tested. For others, NMP may offer the best solubility profile.

[0013] A polar aprotic solvent is a solvent molecule of which comprise at least one heteroatom (e.g. O, N or S) but which does not have a hydrogen atom attached to the heteroatom or, where more than one heteroatom, any of the heteroatoms in the molecule. The polar aprotic solvent (e.g. DMA, DMSO or NMP) may be pharmaceutical grade. The polar aprotic solvent (e.g. DMA) may be the administration vehicle or it may be that the formulation is diluted before use with an administration vehicle which provides desirable characteristics. Thus, the formulation may be ready for infusion and have the polar aprotic solvent (e.g. DMA) as a major component; or it may be a formulation which has the polar aprotic solvent (e.g. DMA) as a major component and is intended to be diluted before administration to generate a formulation which is ready for infusion and has the polar aprotic solvent (e.g. DMA) only as a minor component; or it may be a formulation which is ready for infusion, has the polar aprotic solvent (e.g. DMA) only as a minor component and results from the dilution of a formulation in which polar aprotic solvent (e.g. DMA) is a major component. Thus, the polar aprotic solvent (e.g. DMA) may represent from 0.1% v/v to 100%v/v of the formulation.

[0014] Very few pharmaceutically acceptable solvents dissolve sufficient quantities of protides to deliver a therapeutically effective dose intravenously. Of those that do, many do not form stable solutions and protides will tend to precipitate out. The inventors have surprisingly found that solvents which do generate a stable solution are generally polar aprotic solvents, for example DMA, DMSO and NMP. Of those solvents that have been found to be capable of dissolving protides, the inventors have found that certain polar aprotic solvents, and in particular DMA either on its own or in conjunction with other solubilizers, are particularly able to hold certain protides in solution at a concentration necessary to deliver the required dose when that solution is diluted with an aqueous vehicle. For other protides, NMP was found to be the most effective at holding the protide in solution when that solution is diluted with an aqueous vehicle.

[0015] Thus, the use of polar aprotic solvents, and in particular DMA, provides an advantage over other formulation solvents which, surprisingly, makes it an excellent
medium for delivering protides to patients in a practical and therapeutically effective manner.

[0016] The formulation of the invention may be for dilution by a predetermined amount shortly before administration, i.e. up to 48 hours (e.g. up to 24, 12 or 2 hours) before administration.

[0017] The formulation may also comprise one or more pharmaceutically acceptable solubilizers, e.g. a pharmaceutically acceptable non-ionic solubilizers. Solubilizers may also be called surfactants. Illustrative solubilizers include polyethoxylated fatty acids and fatty acid esters and mixtures thereof. Suitable solubilizers include polyethoxylated castor oil (e.g. that sold under the trade name Kolliphor® ELP); or polyethoxylated stearic acid (e.g. that sold under the trade names Solutol® or Kolliphor® HS15); or polyethoxylated (e.g. polyoxyethylene (20)) sorbitan monooleate, (e.g. that are sold under the trade names Polysorbate 80 or Tween® 80). Tween® 80, a polyethoxylated sorbitan monooleate, for example, has been shown to be particularly effective in formulations of NUC-7738.

[0018] In certain preferred embodiments, the formulation comprises more than one pharmaceutically acceptable solubilizer. Formulations comprising more than one solubilizer have been found to be particularly effective in formulations of NUC-3373.

[0019] The formulation may also comprise an aqueous vehicle. The formulation of the invention may be ready to administer, in which case it will typically comprise an aqueous vehicle.

[0020] The formulation may be for parenteral, e.g. for intravenous, subcutaneous or intramuscular administration. Preferably, the formulation is for intravenous administration. The administration may be through a CVAD or it may be through a peripheral vein.

[0021] The total dose of protide in a formulation suitable for administration will typically be from 250 mg to 5 g, from 250 mg to 3g, from 500 mg to 2 g or from 1 g to 1.5 g.

[0022] While the formulations of the invention are preferably for parenteral administration, certain embodiments of the invention may also be administered orally.

[0023] In a second aspect of the invention is provided a pharmaceutical formulation comprising:

a protide;

a polar aprotic solvent (e.g. DMA); and

optionally one or more pharmaceutically acceptable excipients;

wherein the formulation is for medical use;
wherein the protide is not gemcitabine-[phenyl-benzoxy-L-alaninyl]-phosphate.

[0024] In a third aspect of the invention is provided a pharmaceutical formulation comprising:

5 a protide;

a polar aprotic solvent (e.g. DMA); and

optionally one or more pharmaceutically acceptable excipients;

wherein the formulation is for use in treating cancer;

wherein the protide is not gemcitabine-[phenyl-benzoxy-L-alaninyl]-phosphate.

[0025] The cancer may be a cancer selected from: pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, colorectal cancer, lung cancer, bladder cancer, prostate cancer, cholangiocarcinoma, renal cancer, cervical cancer, thymic cancer, a cancer of an unknown primary origin, lymphoma or leukaemia.

Stock solution formulations

[0026] It may be that the polar aprotic solvent (e.g. DMA) represents 30% or more by volume of the formulation. Thus, it may be that the polar aprotic solvent (e.g. DMA) represents 50% or more, e.g. 60% or more by volume of the formulation. The polar aprotic solvent (e.g. DMA) may represent 95% or less by volume of the formulation, e.g. 90% or less. The formulation may also comprise an aqueous vehicle (e.g. saline). The aqueous vehicle may be present in 50% or less by volume of the formulation, e.g. 30% or less by volume of the formulation. Typically the aqueous vehicle (e.g. saline) will represent 5% or more, e.g. 10% or more, by volume of the formulation.

[0027] It may be that the concentration of the protide in the formulation solvent(s) is 1 g or less per mL. It may be that the concentration of the protide in the formulation solvent(s) is 500 mg or less per mL. It may be that the concentration 100 mg or more per mL. Preferably, the concentration is from 200 mg to 300 mg, e.g. from 225 mg to 275 mg, e.g. about 250 mg, per mL.

[0028] Certain preferred formulations comprise:

from 30 % to 95% by volume DMA;

from 5% to 50% by volume aqueous vehicle; and

from 100 mg to 400 mg (e.g. from 100 mg to 300 mg) per mL protide.

[0029] More preferred formulations comprise:
from 70 % to 90% by volume DMA;
from 10% to 30% by volume aqueous vehicle (e.g. saline); and
from 200 mg to 300 mg per ml_ protide.

[0030] The formulations described in the previous four paragraphs, in which the polar aprotic solvent (e.g. DMA) is present as a major component may be for administering (e.g. by infusion or injection) the formulation without it being diluted prior to said administration. They may, for example, be for administration through a Central Venous Administration Device (CVAD). When administered via a CVAD, the formulation is typically not diluted.

[0031] Alternatively, these formulations may be stock solutions which are diluted prior to use to form a formulation suitable for administration, e.g. through a peripheral vein.

**Surfactant solution formulations**

[0032] It may be that the polar aprotic solvent (e.g. DMA) represents 10% or more, e.g. 20% or more by volume of the formulation. Thus, it may be that the polar aprotic solvent (e.g. DMA) represents 80% or less, e.g. 70% or less by volume of the formulation. The polar aprotic solvent (e.g. DMA) may represent 55% or less by volume of the formulation. The formulation may also comprise one or more solubilizers (e.g. one or more polyethoxylated fatty acids). The one or more solubilizers may represent 70% or less by volume of the formulation, e.g. 60% or less by volume of the formulation. Typically the one or more solubilizers will represent 20% or more, e.g. 35%, by volume of the formulation.

The formulation may also comprise an aqueous vehicle, e.g. in an amount from 1% to 15% by volume or from 5% to 12% by volume.

[0033] It may be that the concentration of the protide in the formulation solvent(s) is 200 mg or less per ml_, e.g. 150mg or less or 130 mg or less. It may be that the concentration is 40 mg or more per ml_, e.g. 60 mg or more. Preferably, the concentration is from 70 mg to 120 mg per ml_, e.g. about 100 mg per ml_.

[0034] Certain preferred formulations comprise:

- from 20 % to 70% by volume DMA;
- from 20% to 70% by volume solubilizer or solubilizers; and
- from 50 mg to 150 mg per ml_ protide. The formulation may also comprise an aqueous vehicle, e.g. in an amount from 1% to 15% by volume.

[0035] Certain particularly preferred formulations comprise:

- from 30 % to 60% by volume DMA;
- from 10% to 35% by volume a first solubilizer;
from 10% to 35% by volume a second solubilizer;
from 2% to 15% an aqueous vehicle; and
from 50 mg to 150 mg per ml_protide. The first solubilizer may be a
polyethoxylated castor oils (e.g. that sold under the trade name Kolliphor® ELP). The
second solubilizer may be a polyethoxylated sorbitan monooleate (e.g. that sold under the
trade name Tween® 80).

[0036] The formulation may comprise:
from 35 % to 50% by volume DMA;
from 15% to 30% by volume the first solubilizer;
from 15% to 30% by volume the second solubilizer;
from 5% to 12% an aqueous vehicle; and
from 50 mg to 150 mg per ml_protide.

[0037] The surfactant solutions formulations described in the previous five paragraphs, in
which the polar aprotic solvent (e.g. DMA) is present as a major component are typically
diluted with an aqueous vehicle prior to administration. They are typically prepared from
the stock solutions mentioned above before being further diluted ready for administration.
Once diluted, they may be administered through a peripheral vein.

[0038] These formulations may be formed by diluting a stock solution formulation that
does not contain any solubilizers with a solution which does contain solubilizers. Protides
can degrade in the presence of certain solubilizers.

Infusion solution formulations

[0039] It may be that the polar aprotic solvent (e.g. DMA) represents 0.1% or more, e.g. 0.5%
or more 1% or more by volume of the formulation. Thus, it may be that DMA
represents 12% or less, e.g. 10% or less or 8% or less by volume of the formulation. The
formulation may also comprise an aqueous vehicle (e.g. saline or WFI). The aqueous
vehicle may be present in 99.5% or less by volume of the formulation, e.g. 99% or 98% or
less by volume of the formulation. Typically the aqueous vehicle will represent 80% or
more, e.g. 95% or more, by volume of the formulation. The formulation may also comprise
one or more solubilizers (e.g. one or more polyethoxylated fatty acids). The one or more
solubilizers may present in 12% or less by volume of the formulation, e.g. 10% or less or
8% or less by volume of the formulation. Typically the one or more solubilizers will be
present in 0.1% or more, e.g. 0.5% or more or 1% or more, by volume of the formulation.
[0040] It may be that the concentration of the protide in the formulation solvent(s) is 15.0 mg or less per mL or 12.0 mg or less per mL, e.g. 10.0 mg or less or 8 mg or less per mL. It may be that the concentration is 1.0 mg or more per mL, e.g. 2.0 mg or more. Preferably, the concentration is from 2.5 mg to 12 mg per mL, e.g. from 3 mg to 11 mg per mL.

[0041] Certain preferred formulations comprise:

- from 0.1 % to 10% by volume DMA;
- from 0.1% to 10% by volume solubilizer or solubilizers;
- from 85% to 99% by volume aqueous vehicle; and
- from 2.0 mg to 12.0 mg per mL protide.

[0042] Certain particularly preferred formulations comprise:

- from 1 % to 8% by volume DMA;
- from 0.5 % to 4% by volume a first solubilizer;
- from 0.5 % to 4% by volume a second solubilizer;
- from 85% to 99% by volume aqueous vehicle; and
- from 2.0 mg to 12.0 mg per mL protide. The first solubilizer may be a polyethoxylated castor oil (e.g. that sold under the trade name Kolliphor® ELP). The second solubilizer may be a polyethoxylated sorbitan monooleate (e.g. that sold under the trade name Tween® 80).

[0043] The infusion solution formulations described in the previous four paragraphs, in which the polar aprotic solvent (e.g. DMA) is present as a minor component, will typically have been prepared by diluting a concentrated solution of the protide with the aqueous vehicle up to 48 hours prior to administration. Said concentrated solution may be either a solution of the protide in a polar aprotic solvent (see under the heading 'stock solution formulation' above) a solution of the protide in mixture of a polar aprotic solvent and a solubilizer (see under the heading 'surfactant solution formulation' above). These formulations in which the polar aprotic solvent (e.g. DMA) is present as a minor component may be administered through a peripheral vein. The low concentrations of the polar aprotic solvent (e.g. DMA) in said formulations mean that they tend not to cause pain upon peripheral administration.
Methods of treatment and kits

[0044] In a fourth aspect of the invention is provided a method of treating cancer, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising:

- a protide;
- a polar aprotic solvent (e.g. DMA); and
- optionally one or more pharmaceutically acceptable excipients;

wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate.

[0045] The method may comprise the steps of:

- diluting a solution comprising the protide, a polar aprotic solvent (e.g. DMA) and optionally one or more pharmaceutically acceptable excipients with an aqueous vehicle to provide a formulation for infusion or injection; and
- administering the formulation for infusion or injection to the subject by infusion or injection.

[0046] The method may comprise the steps of:

- diluting a first solution comprising the protide and a polar aprotic solvent (e.g. DMA) and optionally an aqueous vehicle with a second solution comprising a polar aprotic solvent (e.g. DMA) and one or more solubilizers to form a third solution ('surfactant solution formulation');

- diluting the third solution with an aqueous vehicle to provide a fourth solution (infusion solution formulation'); and
- administering the fourth solution to the subject by infusion or injection.

[0047] The second solution may comprise more than one solubilizer. Typically, the second formulation will not comprise a pharmaceutically active substance.

[0048] The or each dilution may be by a predetermined amount. The second solution may be called a 'diluent solution'.

[0049] The first solution may be a formulation of the first aspect (see under the heading 'stock solution formulation' above). Likewise, the third solution may be a formulation of the first aspect (see under the heading 'surfactant solution formulation' above). Likewise, the fourth solution may be a formulation of the first aspect (see under the heading 'infusion solution formulation' above).
The fourth solution may be administered via a CVAD. Preferably, however, the fourth formulation is administered via a peripheral vein.

The first solution may comprise:
- from 30% to 95% by volume DMA;
- from 5% to 50% by volume aqueous vehicle; and
- from 100 mg to 400 mg (e.g. from 100 mg to 300 mg) per mL protide; and

The second solution may comprise:
- from 10% to 50% by volume DMA;
- from 20% to 60% by volume a first solubilizer;
- from 20% to 60% by volume a second solubilizer.

It may be that the administration step is carried out up to 48 hours (e.g. up to 12 or 2 hours) after the dilution step, e.g. the second dilution step to form the fourth solution.

In a fifth aspect of the invention is provided a kit, the kit comprising:
- a first formulation comprising the polar aprotic (e.g. DMA) and the protide and optionally an aqueous vehicle;
- a second formulation comprising the polar aprotic solvent and one or more solubilizers;
- wherein the protide is not gemcitabine-[phenyl-benzoxy-L-alaniny]-phosphate.

Thus, the kit may comprise:
- a first formulation comprising:
  - from 30% to 95% by volume DMA;
  - from 5% to 50% by volume aqueous vehicle; and
  - from 100 mg to 400 mg (e.g. from 100 mg to 300 mg) per mL a protide; and
- a second formulation comprising:
  - from 10% to 50% by volume DMA;
  - from 20% to 60% by volume a first solubilizer;
  - from 20% to 60% by volume a second solubilizer.

Typically the second formulation will not comprise any active. The kit of the fifth aspect is useful for the preparation of formulations suitable for peripheral administration.

The first formulation is diluted with the second formulation up to 48 h, e.g. up to 24h before
administration to form a third formulation. The third formulation is further diluted with an aqueous vehicle before administration to the desired concentration to form the formulation which is used administered by infusion or injection to the patient. In order to achieve formulations for peripheral administration which are stable with respect to precipitation of the protide, it is typically desirable to include solubilizers. However, protides can be prone to degradation in the presence of such solubilizers. Thus, a two stage dilution method is, in certain embodiments of the invention, the preferable means by which formulations for peripheral administration are achieved.

[0057] The method may comprise:

- flushing a CVAD with a first portion of a first solution, the first solution comprising a polar aprotic solvent (e.g. DMA) and an aqueous vehicle;
- administering a second formulation to the patient via the CVAD, the second formulation comprising the polar aprotic solvent, the aqueous vehicle and the protide; and
- optionally flushing the CVAD with a second portion of the first formulation.

[0058] Preferably, the relative amounts of the polar aprotic solvent and the aqueous vehicle in the first formulation are the same as the relative amounts in the second formulation.

[0059] Thus, the method of treatment may comprise:

- flushing a CVAD with a first portion of a first solution, the first solution comprising:
  - from 30% to 95% by volume DMA;
  - from 5% to 50% by volume aqueous vehicle; and
- administering a second formulation to the patient via the CVAD, the second formulation comprising:
  - from 30% to 95% by volume DMA;
  - from 5% to 50% by volume aqueous vehicle; and
  - from 100 mg to 400 mg (e.g. from 100 mg to 300 mg) per ml protide; and
- optionally flushing the administration device with a second portion of the first formulation. Typically, the first formulation will not comprise an active.

[0060] In a sixth aspect of the invention is provided a kit, the kit comprising:

- a first solution comprising a polar aprotic solvent (e.g. DMA) and an aqueous vehicle; and
a second formulation comprising the polar aprotic solvent, the aqueous vehicle and the protide;

wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate.

[0061] Thus, the kit may comprise:

5 a first formulation comprising:

from 30 % to 95% by volume DMA;

from 5% to 50% by volume aqueous vehicle; and

a second formulation comprising:

from 30 % to 95% by volume DMA;

from 5% to 50% by volume aqueous vehicle; and

10 from 100 mg to 400 mg (e.g. from 100 mg to 300 mg) per ml protide.

[0062] The first formulation will typically not comprise a pharmaceutically active substance. Thus, it will typically not comprise the protide. The first formulation may be provided in two separate vessels or in a single vessel.

[0063] The kit of the sixth aspect of the invention is useful for the intravenous administration of a protide via a CVAD. The CVAD is flushed with the first formulation prior to administration of the second formulation. This mitigates the risk of precipitation of the protide in or at the entrance to the intravenous administration apparatus, i.e. the CVAD, by avoiding the direct contact of the active formulation with aqueous media (e.g. a saline flushing solution). The CVAD may also be flushed with the first formulation after administration of the second formulation. This further prevents precipitation.

Methods of preparing formulations

[0064] In a fifth aspect of the invention is provided a method of preparing a pharmaceutical formulation of a protide for infusion or injection, the method comprising:

25 diluting a solution comprising the protide, a polar aprotic solvent (e.g. DMA) and optionally one or more pharmaceutically acceptable excipients with an aqueous vehicle to provide the formulation for infusion or injection;

wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate.

[0065] The dilution may be by a predetermined amount.

30 [0066] The starting solution may be a formulation of the first aspect (see under the heading 'stock solution formulations' and 'surfactant solution formulations'). Likewise, the formulation for infusion or injection may be a formulation of the first aspect (see under the
heading 'infusion solution formulation' above). It may be that the administration step is carried out up to 48 hours (e.g. up to 12 or 2 hours) after the dilution step.

[0067] The aqueous vehicle may be selected from saline (e.g. 0.9% saline or 0.45% saline), glucose solution and water for infusion (WFI). The aqueous vehicle may be WFI. Alternatively, the aqueous vehicle may be 0.9% saline.

[0068] The osmolarity of the infusion solution is critically dependent on the dose required together with the volume and type of aqueous medium used, (i.e. the amount of surfactant solution used in the saline, and the % saline (0.45 or 0.9%)). Where the formulation is for administration via a peripheral vein, it may be that the aqueous vehicle is selected such that, at the desired dose and volume, the osmolarity of the infusion solution is between 200 mosm/L and 600 mosm/L. Preferably, where the formulation is for administration via a peripheral vein, the aqueous vehicle is selected such that the infusion solution is substantially isotonic with blood (e.g. the osmolarity of the infusion solution is from 250 mosm/L to 400 mosm/L).

[0069] The aqueous vehicle may comprise one or more pharmaceutically acceptable solubilizers (also known as a surfactants), e.g. a pharmaceutically acceptable non-ionic solubilizer. An exemplary solubilizer is polyoxyethylene (20) sorbitan monooleate (marketed as Tween® 80).

**Protides**

[0070] The formulations and formulation methods described in this specification are suitable for the administration of any protide. NUC-1031 (gemcitabine-[phenyl-benzoxy-L-alaninyl]-phosphate or, to give it its full chemical name: 2'-deoxy-2',2'-difluoro-D-cytidine-5'-O-[phenyl (benzoxy- L-alaninyl)] phosphate) is however explicitly excluded from the scope of this application.

[0071] The term 'protide' is readily understood in the art to mean an aryloxy a-amino acid ester phosphoramidate derivative of a nucleoside or nucleoside analogue. Thus, the protide may be a compound having a structure according to formula (I):

![Chemical structure](image)

(I) wherein

R¹ is aryl;
R² is C₁-C₂₄-alkyl, C₃-C₂₄-alkenyl, C₃-C₂₄-alkynyl, C₂-C₄-alkylene-C₃-C₆-cycloalkyl or C₂-C₄-alkylene-aryl;

R³ and R⁴ are each independently selected from H, C₁-C₆-alkyl and C₂-C₆-alkylene-R⁶; or wherein R³ and R⁴ together with the atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl group;

R⁵ is a nucleoside or nucleoside analogue;

R⁶ is independently selected from aryl (e.g. phenyl), imidazole, indole, S Rₐ, O Rₐ, C₀₂Rₐ, C₀₂N RₐRₐ, N RₐRₐ and NH(=NH)NH₂;

wherein any aryl group is either phenyl or naphthyl and wherein any phenyl or naphthyl group is optionally substituted with from 1 to 4 substituents selected from: halo, nitro, cyano, N RₐRₐ, N RₐS (0)₂Rₐ, N RₐC (0)Rₐ, N RₐCON RₐRₐ, N RₐC₀₂Rₐ, O Rₐ; S Rₐ, SOR₂, S₀₂Rₐ, S₀₂N RₐRₐ, C₀₂Rₐ C (0)Rₐ, CON RₐRₐ, C RₐRₐN RₐRₐ, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl and C₁-C₄-haloalkyl;

wherein R⁶ is independently at each occurrence selected from: H and C₁-C₄-alkyl;

and R⁸ is independently at each occurrence selected from: H, and C₁-C₄-alkyl and C(O)-C₁-C₄-alkyl.

[0072] The nucleoside or nucleoside analogue may have the structure:

wherein:

Q is independently selected from O, NRₐ and CH₂;

R⁷ is independently selected from: O Rₐ, S Rₐ, N RₐRₐ; halo (e.g. F), cyano, C₁-C₄-alkyl, C₂-C₄-alkenyl and C₂-C₄-alkynyl;

R⁸ and R⁹ together with the nitrogen to which they are attached form a substituted pyrimidine or a substituted purine; wherein the purine or pyrimidine is substituted with from 1 to 5 groups selected from: O Rₐ, S Rₐ, N RₐRₐ; halo, cyano, C₁-C₄-alkyl, C₂-C₄-alkenyl and C₂-C₄-alkynyl.

n is typically an integer from 0 to 4.

[0073] As will be readily appreciated by the skilled person, where a pyrimidine or purine is substituted with an OH group attached to a carbon atom neighbouring one of the nitrogen atoms in the pyrimidine or purine core, the pyrimidine or purine will typically exist primarily
in the tautomeric form, i.e. one in which there is no double bond between the nitrogen and
the neighbouring carbons but in which there is a double bond between the neighbouring
carbon and the oxygen of the OH group. Said nitrogen may itself be substituted, e.g. with a
Ci-C4-alkyl group.

5 [0074] It may be that \( R^8 \) and \( R^9 \) together with the nitrogen to which they are attached form
a substituted pyrimidine. It may be that \( R^8 \) and \( R^9 \) together with the nitrogen to which they
are attached form a substituted purine.

[0075] The protide may be a compound having a structure according to formula (II):

\[
\begin{align*}
&\text{NH}_2 \\
&\text{R}^1\text{O}\text{P=O} \xrightarrow{\text{NH}} \text{R}^2\text{O} \xrightarrow{\text{R}^3}\text{R}^4
\end{align*}
\]

10 (II) wherein
\( R^1, R^2, R^3 \) and \( R^4 \) are as described above for compounds of formula (I). NUC-1031
is excluded from the scope of this application and thus, for the absence of doubt, where
the protide is a compound of formula (II), it cannot be the case that \( R^1 \) is unsubstituted
phenyl, \( R^2 \) is unsubstituted benzyl, \( R^3 \) is Me and \( R^4 \) is H.

15 [0076] The protide may be a compound having a structure according to formula (III):

\[
\begin{align*}
&\text{F} \\
&\text{R}^1\text{O}\text{P=O} \xrightarrow{\text{NH}} \text{R}^2\text{O} \xrightarrow{\text{R}^3}\text{R}^4
\end{align*}
\]

10 (III) wherein
\( R^1, R^2, R^3 \) and \( R^4 \) are as described above for compounds of formula (I).

[0077] The protide may be a compound having a structure according to formula (IV):
wherein $R_1$, $R_2$, $R_3$ and $R_4$ are as described above for compounds of formula (I); and wherein $Y$ is independently selected from $H$, $F$, $Cl$ and $OMe$. In certain preferred embodiments, $Y$ is $H$. In other preferred embodiments, $Y$ is $F$.

The Protide may be a compound having a structure according to formula (V):

(V) wherein

$R_1$, $R_2$, $R_3$ and $R_4$ are as described above for compounds of formula (I). Protides of formula (V) are derivatives of clofarabine.

The protide may be a compound having a structure according to formula (VI):

(VI) wherein

$R_1$, $R_2$, $R_3$ and $R_4$ are as described above for compounds of formula (I). ProTides of formula (VI) are derivatives of fludarabine.
The protide may be a compound having a structure according to formula (VII):

(VII) wherein

R₁, R₂, R₃ and R₄ are as described above for compounds of formula (I). Protides of formula (VII) are derivatives of cladribine.

5

[0078] The following statements apply to protides of any of formulae (I) to (V). These statements are independent and interchangeable. In other words, any of the features described in any one of the following statements may (where chemically allowable) be combined with the features described in one or more other statements below. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the statements below which describe a feature of that compound, expressed at any level of generality, may be combined so as to represent subject matter which is contemplated as forming part of the disclosure of this invention in this specification.

[0079] It may be that R¹ is substituted or unsubstituted phenyl. It may be that R¹ is substituted or unsubstituted naphthyl (e.g. 1-naphthyl). Preferably, R¹ is unsubstituted phenyl or unsubstituted naphthyl (e.g. 1-naphthyl). Thus, R¹ may be unsubstituted phenyl. Alternatively, R¹ may be or unsubstituted naphthyl (e.g. 1-naphthyl).

[0080] R² is preferably selected such that it comprises five or more carbon atoms. R² may therefore be selected such that it includes six or more carbon atoms. R² is preferably selected such that it comprises only carbon and hydrogen atoms. R² may be selected from C₅-C₇-cycloalkyl, C₆-C₉-alkyl and benzyl, optionally wherein said groups are unsubstituted. R² may be benzyl.

[0081] It may be that R⁴ is H. It may be that R³ is selected from C₁-C₈-alkyl and C₁-C₃-alkylene-R⁶. It may be that R³ is C₁-C₄-alkyl. It may be that R³ is methyl.

[0082] Q is preferably O.

[0083] n may be an integer from 1 to 3. n may be 1. n may be 2. n may be 3.

[0084] The protide is preferably a compound useful in the treatment of cancer.
[0085] Exemplary protides of formula (II) include the compounds described in WO 2005/012327, incorporated herein by reference. Exemplary protides of formula (II) include:

![Chemical Structures]

[0086] Exemplary protides of formula (III) include the compounds described in WO 2012/1 17246, incorporated herein by reference. Exemplary protides of formula (III) include:

![Chemical Structures]
Exemplary protides of formula (IV) include the compounds described in WO2016/083830 (PCT/GB2015/053628), incorporated herein by reference.

Exemplary protides of formula (IV) include:
Exemplary protides of formulae (V), (VI) and (VII) include the compounds described in WO2006/1 00439. Exemplary protides of formula (V) include:

Exemplary protides of formula (VI) include:

Exemplary protides of formula (VII) include:
[0087] It may be that the protide is NUC-3373. It may be that the protide is NUC-3373 and the polar aprotic solvent is DMA. It may be that the protide is NUC-7738. It may be that the protide is NUC-7738 and the polar aprotic solvent is DMA. It may be that the protide is NUC-7738 and the polar aprotic solvent is NMP. It may be that the protide is CPF-448. It may be that the protide is CPF-448 and the polar aprotic solvent is DMA. It may be that the protide is CPF-448 and the polar aprotic solvent is NMP.

[0088] Protides typically comprise a chiral centre at the phosphorous atom. The protide may be present as a mixture of phosphate diastereoisomers, as the (S)-epimer at the phosphorus atom in substantially diastereomerically pure form or as the (R)-epimer at the
phosphorus atom in substantially diastereomerically pure form. 'Substantially
diastereomerically pure' is defined for the purposes of this invention as a diastereomeric
purity of greater than about 90%. If present as a substantially diastereoisomerically pure
form, the protide may have a diastereoisomeric purity of greater than 95%, 98%, 99%, or
even 99.5%. Alternatively, the protide may be present as a mixture of phosphate
diastereoisomers.

[0090] The (R)- and/or (S)-epimers of the protides can be obtained in substantially
diastereomerically pure form by chromatography, e.g. HPLC optionally using a chiral
column. Alternatively, the (R)- and/or (S)-epimers of the protides can be obtained in
substantially diastereomerically pure form by crystallisation from an appropriate solvent or
solvent system. In a further alternative, the (R)- and/or (S)-epimers of the protides can be
synthesised as an diastereomerically pure form using a diastereoselective synthesis. It
may be that any combination of these techniques could be used to provide a
diastereomerically pure form, e.g. a diastereoselective synthesis followed by crystallisation
or chromatography.

DETAILED DESCRIPTION

[0091] The term 'saline' is intended to refer to an aqueous solution of sodium chloride.
Saline solutions of the present invention will typically be sterile and will typically be at a
concentration suitable for use in parenteral administration. Suitable concentrations are up
to 2 w/v% or up to 1 w/v%. To optimise osmolarity different concentrations of saline can
be used in the formulations of the invention, e.g. 0.9% or 0.45%.

[0092] The formulations of the present invention can be used in the treatment of the
human body. They may be used in the treatment of the animal body. In particular, the
compounds of the present invention can be used to treat commercial animals such as
livestock. Alternatively, the compounds of the present invention can be used to treat
companion animals such as cats, dogs, etc.

[0093] The compounds in the formulations of the invention may be obtained, stored and/or
administered in the form of a pharmaceutically acceptable salt. Suitable pharmaceutically
acceptable salts include, but are not limited to, salts of pharmaceutically acceptable
inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric,
sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids
such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, malic, citric,
lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic,
toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic,
stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate, hemioxalate and hemicalcium salts. Preferably, the compound of the invention are not in the form of a salt, i.e. they are in the form of the free base/free acid.

[0094] For the above-mentioned formulations of the invention the dosage administered will, of course, vary with the compound employed, the precise mode of administration, the treatment desired and the disorder indicated. Dosage levels, dose frequency, and treatment durations of compounds of the invention are expected to differ depending on the formulation and clinical indication, age, and co-morbid medical conditions of the patient. The size of the dose for therapeutic purposes of compounds of the invention will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

[0095] A pharmaceutical formulation typically takes the form of a composition in which active compounds, or pharmaceutically acceptable salts thereof, are in association with a pharmaceutically acceptable adjuvant, diluent or carrier. One such pharmaceutically acceptable adjuvant, diluent or carrier in the formulations of the invention is the polar aprotic solvent. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

[0096] The formulations may be suitable for topical application (e.g. to the skin or bladder), for oral administration or for parenteral (e.g. intravenous administration).

[0097] Any solvents used in pharmaceutical formulations of the invention should be pharmaceutical grade, by which it is meant that they have an impurity profile which renders them suitable for administration (e.g. intravenous administration) to humans.

[0098] For oral administration the formulations of the invention may comprise the active compound admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.

[0099] For the preparation of soft gelatine capsules, the active compounds may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the active compounds may be filled into hard gelatine capsules.

[00100] Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, sweetening agents (such as saccharine), preservative agents and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

[00101] Preferably, however the formulations of the invention are for parenteral (e.g. intravenous) administration or for dilution to form a formulation for parenteral (e.g. intravenous) administration. For parenteral (e.g. intravenous) administration the active compounds may be administered as a sterile aqueous or oily solution. Preferably, the active compounds are administered as a sterile aqueous solution.

[00102] The pharmaceutical composition of the invention will preferably comprise from 0.05 to 99 %w (per cent by weight) protide, more preferably from 0.05 to 80 %w protide, still more preferably from 0.10 to 70 %w protide, and even more preferably from 0.10 to 50 %w protide, all percentages by weight being based on total composition.

[00103] Cyclodextrins have been shown to find wide application in drug delivery (Rasheed et al, Sci. Pharm., 2008, 76, 567-598). Cyclodextrins are a family of cyclic oligosaccharides. They act as a 'molecular cage' which encapsulates drug molecules and alters properties of those drug molecules such as solubility. Cyclodextrins comprise (α-1,4)-linked α-D-glucopyranose units. Cyclodextrins may contains 6, 7 or 8 glucopyranose units (designated α-, β- and γ-cyclodextrins respectively). Cyclodextrins used in pharmaceutical formulations are often β-cyclodextrins. The pendant hydroxyl groups can be alkylated with a C1-C6 substituted or unsubstituted alkyl group. Examples of cyclodextrins are α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), sulfobutylether β-cyclodextrin sodium salt, partially methylated β-cyclodextrin. The formulations of the invention may also comprise at least one cyclodextrin.

[00104] The term C_m-C_n refers to a group with m to n carbon atoms.
[00105] The term "alkyl" refers to a linear or branched hydrocarbon group. An alkyl group is monovalent. For example, C₁₋₆-alkyl may refer to methyl, ethyl, n-propyl, /so-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl. The alkyl groups are preferably unsubstituted.

[00106] The term "alkylene" refers to a linear hydrocarbon chain. An alkylene group is divalent. For example, C₁-alkylene may refer to a CH₂ group. C₂-alkylene may refer to -CH₂CH₂- group. The alkylene groups are preferably unsubstituted.

[00107] The term "haloalkyl" refers to a hydrocarbon chain substituted with at least one halogen atom independently chosen at each occurrence from: fluorine, chlorine, bromine and iodine. The halogen atom may be present at any position on the hydrocarbon chain. For example, C₁₋₄-haloalkyl may refer to chloromethyl, fluoromethyl, trifluoromethyl, chloroethyl e.g. 1-chloromethyl and 2-chloroethyl, trichloroethyl e.g. 1,2,2-trichloroethyl, 2,2,2-trichloroethyl, fluoroethyl e.g. 1-fluoromethyl and 2-fluoroethyl, trifluoroethyl e.g. 1,2,2-trifluoroethyl and 2,2,2-trifluoroethyl, chloropropyl, trichloropropyl, fluoropropyl, trifluoropropyl. A halo alkyl group may be a fluoroalkyl group, i.e. a hydrocarbon chain substituted with at least one fluorine atom.

[00108] The term "alkenyl" refers to a branched or linear hydrocarbon chain containing at least one carbon-carbon double bond. The double bond(s) may be present as the E or Z isomer. The double bond may be at any possible position of the hydrocarbon chain. For example, "C₂₋₄-alkenyl" may refer to ethenyl, allyl and butenyl. The alkenyl groups are preferably unsubstituted.

[00109] The term "alkynyl" refers to a branched or linear hydrocarbon chain containing at least one carbon-carbon triple bond. The triple bond may be at any possible position of the hydrocarbon chain. For example, "C₂₋₆-alkynyl" may refer to ethynyl, propynyl, butynyl. The alkynyl groups are preferably unsubstituted.

[00110] The term "cycloalkyl" refers to a saturated hydrocarbon ring system containing 3, 4, 5 or 6 carbon atoms. For example, "3- to 6- membered cycloalkyl" may refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. The cycloalkyl groups are preferably unsubstituted.

[00111] The term "heterocycloalkyl" may refer to a saturated monocyclic group comprising 1 or 2 heteroatoms independently selected from O, S and N in the ring system (in other words 1 or 2 of the atoms forming the ring system are selected from O, S and N). Examples of heterocycloalkyl groups include; piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, tetrahydropyran,
dihydropyran, dioxane, azepine. The heterocycloalkyi groups are preferably unsubstituted or substituted.

[0012] The present invention also includes formulations of all pharmaceutically acceptable isotopically-labelled forms of compound wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number of the predominant isotope usually found in nature.

[0013] Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as $^2$H and $^3$H, carbon, such as $^{11}$C, $^{12}$C and $^{14}$C, chlorine, such as $^{35}$Cl, fluorine, such as $^{18}$F, iodine, such as $^{123}$I and $^{125}$I, nitrogen, such as $^{13}$N and $^{15}$N, oxygen, such as $^{15}$O, $^{17}$O and $^{18}$O, phosphorus, such as $^{32}$P, and sulphur, such as $^{35}$S.

[0014] Certain isotopically-labelled compounds, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. $^3$H, and carbon-14, i.e. $^{14}$C, and $^{18}$F are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

[0015] Substitution with heavier isotopes such as deuterium, i.e. $^2$H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

[0016] Isotopically-labelled compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.

[0017] The method of treatment or the formulation for use in the treatment of cancer, lymphoma or leukemia may involve, in addition to the formulations of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include the administration of one or more other active agents.

[0018] Where a further active agent is administered as part of a method of treatment of the invention, such combination treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within a therapeutically effective dosage range described hereinbefore and the one or more other pharmaceutically-active agent(s) within its approved dosage range.
[001 19] Thus, the pharmaceutical formulations of the invention may comprise another active agent.

[00120] The one or more other active agents may be one or more of the following categories of anti-tumor agents:

(i) antiproliferative/antineoplastic drugs and combinations thereof, such as alkylating agents (for example cyclophosphamide, nitrogen mustard, bendamustine, melphalan, chlorambucil, busulfan, temozolomide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, pemetrexed, cytosine arabinoside, and hydroxyurea); antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinesis inhibitors); proteasome inhibitors, for example carfilzomib and bortezomib; interferon therapy; and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, mitoxantrone and camptothecin);

(ii) cytostatic agents such as antiestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;

(iii) anti-invasion agents, for example dasatinib and bosutinib (SKI-606), and metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase;

(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies, for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as gefitinib, erlotinib and 6-acrylamido-V-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; modulators of protein regulators of cell apoptosis (for example Bcl-2 inhibitors); inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of
serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib, tipifarnib and lonafarnib), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, PI3 kinase inhibitors, CSF-1 R kinase inhibitors, IGF receptor, kinase inhibitors; aurora kinase inhibitors and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™); thalidomide; lenalidomide; and for example, a VEGF receptor tyrosine kinase inhibitor such as vandetanib, vatalanib, sunitinib, axitinib and pazopanib;

(vi) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2;

(vii) immunotherapy approaches, including for example antibody therapy such as alemtuzumab, rituximab, ibritumomab tiuxetan (Zevalin®) and ofatumumab; interferons such as interferon α; interleukins such as IL-2 (aldesleukin); interleukin inhibitors for example IRAK4 inhibitors; cancer vaccines including prophylactic and treatment vaccines such as HPV vaccines, for example Gardasil, Cervarix, Oncophage and Sipuleucel-T (Provenge); and toll-like receptor modulators for example TLR-7 or TLR-9 agonists;

(viii) cytotoxic agents for example fludarabine (fludara), cladribine, pentostatin (Nipent™);

(ix) steroids such as corticosteroids, including glucocorticoids and mineralocorticoids, for example aclometasone, aclometasone dipropionate, aldosterone, amcinonide, beclomethasone, beclomethasone dipropionate, betamethasone, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, clobetasone, clobetasone butyrate, clobetasol propionate, cloprednol, cortisone, cortisone acetate, cortivazol, deoxycortone, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, dexamethasone isonicotinate, difluorocortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortisone, fluocortolone, fluocortolone caproate, fluocortolone pivalate, fluorometholone, fluprednidene, fluprednidene acetate, flurandrenolone, fluticasone, fluticasone propionate, halcinonide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone valerate, icomethasone, icomethasone enbutate, meprednisone, methylprednisolone, mometasone paramethasone, mometasone furoate monohydrate, prednicarbate, prednisolone, prednisone, tixocortol, tixocortol pivalate, triamcinolone, triamcinolone acetonide, triamcinolone alcohol and their respective pharmaceutically
acceptable derivatives. A combination of steroids may be used, for example a combination of two or more steroids mentioned in this paragraph;

(x) targeted therapies, for example PI3Kδ inhibitors, for example idelalisib and perifosine; or compounds that inhibit PD-1, PD-L1 and CAR T.

[00121] The one or more other active agents may also be antibiotic.

[00122] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of them mean "including but not limited to", and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

[00123] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

[00124] The reader’s attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

[00125] The following abbreviations are used in this specification:

- DMA - dimethylacetamide
- DMSO - dimethylsulfoxide
- NMP - /ν-methylpyrrolidinone
- DMF - A/,A/-dimethylformamide
- IPA - isopropyl alcohol
- PEG - polyethylene glycol
EXAMPLES

Example 1 - Solubility of NUC-3373

The solubility of NUC-3373 (mixture of diastereoisomers) in a range of solvents is shown in Table 1.

Table 1: Solubility of NUC-3373 in a range of pharmaceutically relevant solvents

<table>
<thead>
<tr>
<th>Solvent</th>
<th>NUC-3373 (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol</td>
<td>778</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>449</td>
</tr>
<tr>
<td>PEG 400</td>
<td>422</td>
</tr>
<tr>
<td>NMP</td>
<td>705</td>
</tr>
<tr>
<td>DMSO</td>
<td>948</td>
</tr>
<tr>
<td>DMA</td>
<td>950</td>
</tr>
<tr>
<td>Water</td>
<td>&lt;2.0</td>
</tr>
</tbody>
</table>

As can readily be seen, the solubility of NUC-3373 in water is extremely low. Of the solvents tested, the polar aprotic solvents and particularly DMSO and DMA offered the best solubilities.

Example 2 - Development of an aqueous formulation of NUC-3373.

The successful development of the Diluent Solution to enable preparation of the NUC-1031 aqueous formulation prompted its development for an aqueous formulation of NUC-3373. An aqueous NUC-3373 formulation was developed by adding 6.7ml of a 250mg/ml solution of NUC-3373 in 80% DMA:20% 0.9% saline to 10ml diluent solution to generate a 100mg/ml NUC-3373 surfactant solution (see Table 4), prior to subsequent dilution into an infusion bag.

The clinical dose for NUC-3373 has yet to be established, but the estimated maximum dose may be up to 3,000mg, which set the upper limit for the formulation development studies. Table 2 shows the volume of 100mg/ml NUC-3373 surfactant solution that is required to be added to a 250ml infusion bag for a variety of doses, and the resulting composition of the aqueous infusion solution.
Table 2: Composition of saline infusion solution across a variety of doses of NUC-3373.

<table>
<thead>
<tr>
<th>NUC-3373 Dose (mg)</th>
<th>1,000mg</th>
<th>2,000mg</th>
<th>3,000mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>NUC-3373 Concentration</td>
<td>3.85mg/ml</td>
<td>7.41mg/ml</td>
<td>10.72mg/ml</td>
</tr>
<tr>
<td>Surfactant solution volume</td>
<td>10.0ml</td>
<td>19.9ml</td>
<td>29.9ml</td>
</tr>
</tbody>
</table>

The stability of the 100mg/ml NUC-3373 surfactant solution under two storage conditions (5°C and 20°C) has been shown to be stable for 48 hours at both conditions (see Table 3).

Table 3: Stability of 100mg/ml NUC-3373 surfactant solution.

<table>
<thead>
<tr>
<th></th>
<th>0 hours</th>
<th>8 hours</th>
<th>24 hours</th>
<th>48 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5°C</td>
<td>20°C</td>
<td>5°C</td>
<td>20°C</td>
</tr>
<tr>
<td>Assay content (mg/ml)</td>
<td>105.5</td>
<td>104.8</td>
<td>102.5</td>
<td>100.7</td>
</tr>
<tr>
<td>Purity (% area)</td>
<td>96.1</td>
<td>96.2</td>
<td>96.2</td>
<td>96.1</td>
</tr>
<tr>
<td>pH</td>
<td>7.8</td>
<td>7.8</td>
<td>7.9</td>
<td>7.8</td>
</tr>
<tr>
<td>Appearance</td>
<td>Clear and yellowish</td>
<td>Clear and yellowish</td>
<td>Clear and yellowish</td>
<td>Clear and yellowish</td>
</tr>
</tbody>
</table>

The stability of the aqueous infusion solution was also evaluated using three different doses of NUC-3373 (1,000mg, 2,000mg and 3,000mg) diluted in 250ml 0.9% saline bags at two storage conditions (5°C and 20°C). The results shown in Tables 4, 5 and 6,
demonstrate that the aqueous infusion solutions at all dose strengths are stable for up to 48 hours under both storage conditions.

Table 4: Stability of 1,000mg NUC-3373 in 250ml 0.9% saline infusion bag.

<table>
<thead>
<tr>
<th></th>
<th>0 hours</th>
<th>8 hours</th>
<th>24 hours</th>
<th>48 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5°C</td>
<td>20°C</td>
<td>5°C</td>
<td>20°C</td>
</tr>
<tr>
<td>Assay content</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUC-3373 (mg/ml)</td>
<td>3.7</td>
<td>3.9</td>
<td>3.6</td>
<td>3.7</td>
</tr>
<tr>
<td>Total NUC-3373</td>
<td>960.9</td>
<td>1012.8</td>
<td>934.9</td>
<td>960.9</td>
</tr>
<tr>
<td>(mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purity (%)</td>
<td>96.2</td>
<td>96.1</td>
<td>96.1</td>
<td>96.1</td>
</tr>
<tr>
<td>(area)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>5.5</td>
<td>5.6</td>
<td>5.6</td>
<td>5.5</td>
</tr>
<tr>
<td>Osmolarity</td>
<td>457</td>
<td>462</td>
<td>450</td>
<td>459</td>
</tr>
<tr>
<td>(mosm/L H2O)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appearance</td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
</tr>
</tbody>
</table>

Table 5: Stability of 2,000mg NUC-3373 in 250ml 0.9% saline infusion bag.

<table>
<thead>
<tr>
<th></th>
<th>0 hours</th>
<th>8 hours</th>
<th>24 hours</th>
<th>48 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5°C</td>
<td>20°C</td>
<td>5°C</td>
<td>20°C</td>
</tr>
<tr>
<td>Assay content</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUC-3373 (mg/ml)</td>
<td>7.2</td>
<td>7.4</td>
<td>7.0</td>
<td>7.5</td>
</tr>
</tbody>
</table>
Table 6: Stability of 3,000mg NUC-3373 in 250ml 0.9% saline infusion bag.

<table>
<thead>
<tr>
<th></th>
<th>0 hours</th>
<th>8 hours</th>
<th>24 hours</th>
<th>48 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5°C</td>
<td>20°C</td>
<td>5°C</td>
<td>20°C</td>
</tr>
<tr>
<td>Assay content</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUC-3373 (mg/ml)</td>
<td>10.2</td>
<td>10.4</td>
<td>10.4</td>
<td>10.5</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUC-3373 (mg)</td>
<td>2857</td>
<td>2913</td>
<td>2913</td>
<td>2941</td>
</tr>
<tr>
<td>Purity (%) area</td>
<td>96.1</td>
<td>96.1</td>
<td>96.2</td>
<td>96.1</td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.5</td>
<td>5.5</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Osmolarity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(mosm/L H20)</td>
<td>831</td>
<td>818</td>
<td>823</td>
<td>812</td>
</tr>
<tr>
<td>Appearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
<td>Clear and colourless</td>
</tr>
</tbody>
</table>

5 The pH and osmolarity of the 1,000mg and 2,000mg dose solutions in a 250ml 0.9% saline bag are suitable for intravenous administration via either a CVAD or peripheral vein.
Aqueous infusion solutions

The stability studies described above used 250ml 0.9% saline bags as the base infusion solution, however similar stability results have been demonstrated if alternative aqueous infusion solutions were used (e.g. Water for Injection (WFI), 0.45% saline) or the volume of the infusion bag was increased (e.g. 500ml). Lower saline concentrations or increased volume of infusion do not affect the stability over 48 hours, and do not significantly alter the pH, and serve to reduce the osmolarity of the infusion solution. For example, using 0.45% saline or WFI reduces the osmolarity of the high dose NUC-3373 (10mg/ml) from 812 mosm/l to 715 and 557 mosm/l H2O respectively, whereas increasing the volume of the 0.9% saline infusion bag from 250ml to 500ml at the high dose (3,000mg) NUC-3373 infusion solution reduces the osmolarity from 812 mosm/l to 524 mosm/l. These alternative infusion solutions may make the high dose NUC-3373 aqueous based formulation suitable for peripheral vein infusion as well as CVAD infusion.

Example 3 - Illustrative description of a formulation methodology

A formulation methodology (see WO2015/1 98059 (PCT/GB2015/051 858)) has been developed for the intravenous administration of protides. This methodology has been shown in clinical trials to be effective for NUC-1031 which has broadly the same solubility profile as NUC-3373 and NUC-7738. That methodology is as follows:

A 250 mg/mL solution of the protide (the S-epimer, the R epimer or a mixture thereof) is formed in an 80:20 (by volume) mixture of DMA and 0.9% saline. This stock solution formulation is typically sufficient for long term storage and transport of protides.

This stock solution formulation can be administered to patients intravenously via a CVAD (e.g. a Hickman line, PICC line). The intravenous administration apparatus will typically be flushed with an 80:20 (by volume) mixture of DMA and 0.9% saline both before and after administration of the formulation comprising the protide. This helps mitigate the risk of any potential precipitation of protide in the intravenous administration apparatus on contact with the saline flush.

Alternatively, where intravenous administration using a saline bag infusion is the preferred method of administration, the stock solution formulation is diluted to 100 mg/mL with a diluent solution which is 20%:40%:40% mixture of DMATween ® 80:Kolliphor® ELP (e.g. 6.7 mL of 250 mg/ml protide in 80:20 DMA:0.9% saline is added to 10 mL of the DMA:Tween®80:Kolliphor® ELP diluent solution). The resultant (surfactant solution) formulation is typically stable for up to 5 days.

The infusion solution formulation is then prepared by diluting this surfactant solution formulation to the desired concentration with 0.9% saline.
For NUC-1031, solutions of either the S-isomer alone or a mixture of the R and S epimers at 4, 8 and 10 mg/mL have been shown to be stable (both to precipitation of NUC-1031 and to degradation of NUC-1031) for 48 hours after dilution of this formulation in both 0.45% and 0.9% saline at a range of pHs (4.5, 6.0 and 7.0), providing the mixtures were not stirred. The osmolarity of all of the NUC-1031 solutions has also been shown to be acceptable for peripheral administration.

In a clinical trial of NUC-3373, this administration methodology has allowed NUC-3373 to be successfully administered via a CVAD. Early results are that the infusion solutions of NUC-3373 prepared as described in this example have some efficacy in treating cancer.

**Example 4 - Solubility of NUC-7738**

The solubility of NUC-7738 in a range of solvents is shown in **Table 7**.

**Table 7**: Solubility of NUC-7738 (mixture of diastereoisomers) in a range of solvents

<table>
<thead>
<tr>
<th>Solvent</th>
<th>NUC-7738 (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol</td>
<td>&gt;667</td>
</tr>
<tr>
<td>Propylene Glycol</td>
<td>&gt;667</td>
</tr>
<tr>
<td>DMSO</td>
<td>&gt;667</td>
</tr>
<tr>
<td>NMP</td>
<td>&gt;667</td>
</tr>
<tr>
<td>DMA</td>
<td>&gt;667</td>
</tr>
<tr>
<td>Heptane</td>
<td>&lt;12</td>
</tr>
<tr>
<td>1-butylmethylether</td>
<td>&lt;11</td>
</tr>
<tr>
<td>isopropylacetate</td>
<td>&lt;9</td>
</tr>
<tr>
<td>Water</td>
<td>&lt;5.2</td>
</tr>
<tr>
<td>5% Tween in water</td>
<td>&lt;11.8</td>
</tr>
</tbody>
</table>

As can readily be seen, the solubility of NUC-7738 in water is extremely low, even when the water incorporates a solubiliser. NUC-7738 is, however, soluble in polar solvents, including NMP, DMSO and DMA.
Example 5 - Development of an aqueous formulation of NUC-7738

50 µL of a 100 mg/mL concentrate of NUC-7738 (mixture of diastereoisomers) in a range of solvents (DMA, DMSO, NMP, ethanol, benzyl alcohol) was mixed with 50 µL of Tween® 80 and added to 1.150 mL saline and the resultant solutions were checked by eye for precipitation of NUC-7738. Similarly a 50 µL concentrate of NUC-7738 (mixture of diastereoisomers) in Tween® 80 was mixed with 50 µL water for injection and then added to 1.150 mL saline. The results are shown in table 8.

Table 8

<table>
<thead>
<tr>
<th>Solvents</th>
<th>WFI</th>
<th>Saline</th>
<th>Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMA 50</td>
<td>50</td>
<td>1150</td>
<td>Clear and limpid solution</td>
</tr>
<tr>
<td>DMSO 50</td>
<td>50</td>
<td>1150</td>
<td>Clear and limpid solution</td>
</tr>
<tr>
<td>NMP 50</td>
<td>50</td>
<td>1150</td>
<td>Clear and limpid solution</td>
</tr>
<tr>
<td>EtOH 50</td>
<td>50</td>
<td>1150</td>
<td>White precipitate, milky solution</td>
</tr>
<tr>
<td>BnOH 50</td>
<td>50</td>
<td>1150</td>
<td>White precipitate, milky solution</td>
</tr>
<tr>
<td>TW80 50</td>
<td>50</td>
<td>1150</td>
<td>White precipitate, milky solution</td>
</tr>
</tbody>
</table>

Table 8 shows that DMSO, DMA and NMP are much more effective at retaining NUC-7738 in aqueous solution than other solvents, for example, ethanol in which NUC-7738 has good solubility in non-aqueous conditions. Even a solubiliser is not effective, in the absence of a polar aprotic solvent, at retaining NUC-7738 in solution in aqueous conditions.

The solutions prepared above were assayed for NUC-7738 content and purity on being formed and also after 48h. Both the assay content and the purity were substantially unchanged after 48 h, indicating that the solutions were chemically and physically stable over this period.
In a further experiment, the minimum concentration of NUC-7738 in solvents that could be diluted with saline without precipitation was determined. Solutions of NUC-7738 (mixture of diastereoisomers) at various concentrations in NMP, DMSO and DMA were prepared and 100 µL of the solutions were added to 2.40 mL saline. The resultant aqueous solutions were observed for precipitation of NUC-7738. The results are provided in Table 9.

### Table 9

<table>
<thead>
<tr>
<th>Concentrate solutions NUC-7738</th>
<th>Saline</th>
<th>Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMP 100mg/ml</td>
<td>NMP 50mg/ml</td>
<td>DMSO 100mg/ml</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As can be seen, the best solvent for retaining NUC-7738 in aqueous solution appeared to be NMP which provided a clear and limpid solution when a 25 mg/mL solution was diluted with saline.
Claims

1. A pharmaceutical formulation comprising:
   a protide;
   a polar aprotic solvent; and
   optionally one or more pharmaceutically acceptable excipients;
   wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate (NUC-1031).
2. A formulation of claim 1, wherein the polar aprotic solvent is selected from dimethyl acetamide (DMA) dimethylsulfoxide (DMSO) and N-methylpyrrolidone (NMP).
3. A formulation of claim 1, wherein the polar aprotic solvent is DMA.
4. A formulation according to any one of claims 1 to 3, wherein the formulation also comprises an aqueous vehicle.
5. A formulation according to claim 4, wherein the aqueous vehicle is saline.
6. A formulation according to claim 4, wherein the aqueous vehicle is WFI.
7. A formulation according to any one of claims 1 to 6, wherein the formulation also comprises a solubilizer.
8. A formulation according to claim 7, wherein the formulation comprises two or more solubilizers.
9. A formulation according to claim 7 or claim 8, wherein the or each solubilizer is a polyethoxylated fatty acid or a mixture thereof.
10. A formulation according to claim 1, wherein the formulation comprises:
    from 30% to 95% by volume DMA;
    from 5% to 50% by volume aqueous vehicle; and
    from 100 mg to 400 mg per ml protide.
11. A formulation according to claim 1, wherein the formulation comprises
    from 30% to 60% by volume DMA;
    from 10% to 35% by volume a first solubilizer;
    from 10% to 35% by volume a second solubilizer;
    from 2% to 15% an aqueous vehicle; and
    from 50 mg to 150 mg per ml protide.
12. A formulation according to claim 1, wherein the formulation comprises:
   from 0.1 % to 10% by volume DMA;
   from 0.1% to 10% by volume solubilizer or solubilizers;
   from 85% to 99% by volume aqueous vehicle; and
   from 2.0 mg to 12.0 mg per ml protide.

13. A formulation according to claim 12, wherein the formulation comprises:
   from 1 % to 8% by volume DMA;
   from 0.5 % to 4% by volume a first solubilizer;
   from 0.5 % to 4% by volume a second solubilizer;
   from 85% to 99% by volume aqueous vehicle; and
   from 2.0 mg to 12.0 mg per ml protide.

14. A formulation according to any preceding claim wherein the protide is 5-fluoro-2'-deoxyuridine-5'-0-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373).

15. A formulation according to any one of claims 1 to 13, wherein the protide is 3'-deoxyadenosine-5'-0-[phenyl(benzyloxy-L-alaninyl)] phosphate (NUC-7738).

16. A formulation according to any one of claims 1 to 13, wherein the protide is 2-chloro-2'-beta-fluoro-2'-deoxyadenosine-5'-[phenyl-(benzoxy-L-(alaninyl)]-phosphate (CPF-448).

17. A formulation according to any preceding claim for use in treating cancer.

18. A method of treating cancer, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising:
   a protide;
   a polar aprotic solvent; and
   optionally one or more pharmaceutically acceptable excipients;
   wherein the protide is not gemcitabine-[phenyl-benzoxy -L-alaninyl]-phosphate (NUC-1031).

19. A method of claim 18, wherein the method comprises the steps of:
   diluting a first solution comprising the protide and a polar aprotic solvent and
   optionally an aqueous vehicle with a second solution comprising a polar aprotic solvent and
   one or more solubilizers to form a third solution;
diluting the third solution with an aqueous vehicle to provide a fourth solution; and
administering the fourth solution to the subject by infusion or injection.

20. A method of claim 18, the method comprising:
flushing a Central Venous Administration Device (CVAD) with a first portion of a first solution, the first solution comprising a polar aprotic solvent and an aqueous vehicle;
administering a second formulation to the patient via the CVAD, the second formulation comprising the polar aprotic solvent, the aqueous vehicle and the protide; and
optionally flushing the CVAD with a second portion of the first formulation.

21. A method of any of claims 18 to 20, wherein the polar aprotic solvent is DMA.

22. A method of any of claims 18 to 21, wherein the protide is 5-fluoro-2'-deoxyuridine-5'-0-[1-naphthyl (benzoxyl-L-alaninyl)] phosphate (NUC-3373).

23. A formulation of any of claims 18 to 21, wherein the protide is 3'-deoxyadenosine-5'-0-[phenyl(benzoxyl-L-alaninyl)] phosphate (NUC-7738).

24. A formulation of any of claims 18 to 21, wherein the protide is 2-chloro-2'-beta-fluoro-2'-deoxyadenosine-5'-[phenyl-(benzoxy-L-(alaninyl)]-phosphate (CPF-448).

25. A kit, the kit comprising:
a first formulation comprising the polar aprotic and the protide and optionally an aqueous vehicle;
a second formulation comprising the polar aprotic solvent and one or more solubilizers;
wherein the protide is not gemcitabine-[phenyl-benzoxyl -L-alaninyl]-phosphate.

26. A kit, the kit comprising:
a first solution comprising a polar aprotic solvent and an aqueous vehicle; and
a second formulation comprising the polar aprotic solvent, the aqueous vehicle and the protide;
wherein the protide is not gemcitabine-[phenyl-benzoxyl -L-alaninyl]-phosphate (NUC-1031).

27. A kit of claim 25 or claim 26, wherein the polar aprotic solvent is DMA.
28. A kit of any of claims 25 to 27, wherein the protide is NUC-3373 5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxyl-L-alaniny)] phosphate (NUC-3373).

29. A kit of any of claims 25 to 27, wherein the protide is 3'-deoxyadenosine-5'-O-[phenyl(benzyloxy-L-alaniny)] phosphate (NUC-7738).

30. A kit of any of claims 25 to 27, wherein the protide is 2-chloro-2'-beta-fluoro-2'-deoxyadenosine-5'-[phenyl-(benzoxy-L-(alaniny)]-phosphate (CPF-448).
A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K9/00  A61K9/08  A61K31/7072  A61K31/7076  A61P35/00

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>wo 2012/117246 AI (NUCANA BIOMED LTD [GB]) ; MCGUIGAN CHRISTOPHER [GB] ; BALZARINI JAN [BE] ; 7 September 2012 (2012-09-07) cited in the application</td>
<td>1, 2, 4, 9, 14, 17-20, 22, 25, 26, 28</td>
</tr>
<tr>
<td>Y</td>
<td>claims 16, 17 page 70, lines 14-16, 27-28 ----- /-----</td>
<td>1-29</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

**A** document defining the general state of the art which is not considered to be of particular relevance

**E** earlier application or patent but published on or after the international filing date

**L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but later than the priority date claimed

**I** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**A** document member of the same patent family

Date of the actual completion of the international search 21 February 2017

Date of mailing of the international search report 21/03/2017

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Peri's Antoli, Berta
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>MCGUIGAN CHRISTOPHER ET AL: &quot;Phosphorami date ProTi des of the Anti cancer Agent FUDR Successful ly Del i ver the Preformed Bi acti ve Monophosphate i n Cells and Confer Advantage over the Parent Nucl eosi de&quot;, JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 20, 27 October 2011 (2011-10-27), pages 7247-7258, XP055023640, ISSN: 0022-2623, DOI: 10.1021/jm200815w</td>
<td>1, 2, 4-9, 12-14, 17-20, 25, 26</td>
</tr>
<tr>
<td>Y</td>
<td>Scheme 1, page 7256, column 1, paragraph 2-3</td>
<td>1-29</td>
</tr>
<tr>
<td>X</td>
<td>US 2012/052046 Al (CHAMBERLAIN STANLEY ET AL) 1 March 2012 (2012-03-01)</td>
<td>1-9, 12, 13, 25-27</td>
</tr>
<tr>
<td>X</td>
<td>LIU ANG ET AL: &quot;Chal lenges and sol uti ons i n the bioanalis s of BMS-986094 and its metabol i tes i ncl udi ng a highly pol ar, acti ve nucl eosi de tri phosphate i n plasma and t i sses usi ng LC-M&quot;, JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES &amp; APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 1000, 13 July 2015 (2015-07-13), pages 29-40, XP029257808, ISSN: 1570-0232, DOI: 10.1016/J.CHROMB.2015.07.006</td>
<td>1, 2, 7, 8</td>
</tr>
<tr>
<td>Y</td>
<td>abstract, page 31, column 1, paragraph 4</td>
<td>1-16, 25-29</td>
</tr>
<tr>
<td>X</td>
<td>GRIFFITH T M ET AL: &quot;Enhanced i nhibiti on of the EDHF phenomenon by a phenyl methoxyal anyl phosphorami date deri vati ve of di deoxyadenosi ne&quot;, BRITISH JOURNAL OF PHARMACOLOGY, vol. 142, no. 1, May 2004 (2004-05), pages 27-30, XP002379994, ISSN: 0007-1188, DOI: 10.1038/SJ.BJP.0705782</td>
<td>1, 2</td>
</tr>
<tr>
<td>Y</td>
<td>page 28, column 1, paragraph 4</td>
<td>1-16, 25-29</td>
</tr>
</tbody>
</table>
## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>wo 2006/100439 Al (UNIV CARDIFF [GB]) ; MCGUIGAN CHRISTOPHER [GB] ; MII LL S KENNETH [US] ; CONG 28 September 2006 (2006-09-28) cited in the application claims 1, 19, 26 page 13, paragraph 2</td>
<td>1-9, 16-20, 24-26,29</td>
</tr>
<tr>
<td>Y</td>
<td>Y cited in the application claims 19, 26 page 13, paragraph 2</td>
<td>1-29</td>
</tr>
<tr>
<td>X, P</td>
<td>wo 2016/083830 Al (NUCANA BIOMED LTD [GB]) 2 June 2016 (2016-06-02) cited in the application claims 1-19 page 13, paragraph 2</td>
<td>1-9, 15, 17-20, 23,25, 26,29</td>
</tr>
<tr>
<td>Y, P</td>
<td>Y, P cited in the application claims 1-25 page 13, paragraph 2</td>
<td>1-29</td>
</tr>
</tbody>
</table>

---

Form PCT/ISA/210 (continuation of second sheet) (April 2008)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>wO 2012117246</td>
<td>07-09-2012</td>
<td>AU 2012223012 AI</td>
<td>02-05-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 112013021986 A2</td>
<td>16-11-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2828326 AI</td>
<td>07-09-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103403013 A</td>
<td>20-11-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 104974206 A</td>
<td>14-10-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 2681227 T3</td>
<td>22-02-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2681227 AI</td>
<td>08-01-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 3031812 AI</td>
<td>15-06-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2569185 T3</td>
<td>09-05-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1192758 AI</td>
<td>21-10-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HR P20160346 TI</td>
<td>06-05-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 228169 A</td>
<td>31-07-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5978232 B2</td>
<td>24-08-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2014506913 A</td>
<td>20-03-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20140023913 A</td>
<td>27-02-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 615270 A</td>
<td>25-09-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2013143862 A</td>
<td>10-04-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 192841 AI</td>
<td>30-09-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI 2681227 TI</td>
<td>29-04-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SM T201600132 B</td>
<td>01-07-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2014057866 AI</td>
<td>27-02-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2015183817 AI</td>
<td>02-07-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2016166596 AI</td>
<td>16-06-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2012117246 AI</td>
<td>07-09-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 201306468 B</td>
<td>29-04-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012052046 AI</td>
<td>01-03-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2010203416 AI</td>
<td>28-07-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI 1004575 A2</td>
<td>05-04-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2749394 AI</td>
<td>15-07-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102348712 A</td>
<td>08-02-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EA 201170915 AI</td>
<td>28-02-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC SP11011249 A</td>
<td>31-01-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2385951 A2</td>
<td>16-11-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2012514657 A</td>
<td>28-06-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 2011012886 A</td>
<td>04-11-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PE 00132012 AI</td>
<td>02-02-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 179291 AI</td>
<td>29-08-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012052046 AI</td>
<td>01-03-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010081082 A2</td>
<td>15-07-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 201104978 B</td>
<td>28-03-2012</td>
</tr>
<tr>
<td>wO 2006100439</td>
<td>28-09-2006</td>
<td>AT 471334 T</td>
<td>15-07-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2006226182 AI</td>
<td>28-09-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI0609704 A2</td>
<td>20-04-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2602324 AI</td>
<td>28-09-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101175763 A</td>
<td>07-05-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103936807 A</td>
<td>23-07-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CY 1111538 TI</td>
<td>05-08-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1866324 T3</td>
<td>27-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1866324 A</td>
<td>19-12-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2348741 T3</td>
<td>13-12-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 186104 A</td>
<td>27-06-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5345381 B2</td>
<td>20-11-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5863702 B2</td>
<td>17-02-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008533191 A</td>
<td>21-08-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013173786 A</td>
<td>05-09-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1866324 E</td>
<td>16-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI 1866324 TI</td>
<td>29-10-2010</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
<td>Publication date</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>US 2009215715 A1</td>
<td>27-08-2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WO 2006100439 A1</td>
<td>28-09-2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZA 200709011 B</td>
<td>28-01-2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WO 2016083830 A1</td>
<td>02-06-2016</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>wo 2015198059 A1</td>
<td>30-12-2015</td>
<td>AU 2015278900 A1</td>
<td>27-10-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2944966 A1</td>
<td>30-12-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 11201608809R A</td>
<td>29-11-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2015198059 A1</td>
<td>30-12-2015</td>
</tr>
</tbody>
</table>